GLPwatch
Byetta for Chronic kidney disease
exenatide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCByetta (exenatide) is not FDA-approved for chronic kidney disease, and any use for this condition is off-label or investigational. Research includes studies on its renal effects in diabetes patients and animal models, but no direct approval for treating chronic kidney disease.
AI summary of the sources below.
| Drug | Byetta (exenatide) |
|---|---|
| Condition | Chronic kidney disease |
| Approval status | Investigational / off-label |
| Research papers | 36 |
Byetta is not FDA-approved for chronic kidney disease; the research below reflects investigational or off-label study only.
Research on exenatide for chronic kidney disease (36)
- Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial.
- Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men.
- Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial.
- Exenatide reduces urinary transforming growth factor-β1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria.
- Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.
- The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats.
- Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis.
- Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial.
- Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial.
- Exaggerated liver injury induced by renal ischemia reperfusion in diabetes: effect of exenatide.
- Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers.
- Effect of combined therapy of mesenchymal stem cells with GLP-1 receptor agonist, exenatide, on early-onset nephropathy induced in diabetic rats.
- Acute tubulointerstitial nephritis following treatment with exenatide.
- Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials.
- Exenatide Attenuates Obesity-Induced Mitochondrial Dysfunction by Activating SIRT1 in Renal Tubular Cells.
- Preparation of exenatide-loaded linear poly(ethylene glycol)-brush poly(l-lysine) block copolymer: potential implications on diabetic nephropathy.
- Effects of exenatide on kidney function, adverse events, and clinical end points of kidney disease in type 2 diabetes.
- Observational study of kidney function and albuminuria in patients with type 2 diabetes treated with exenatide BID versus insulin glargine.
- Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease.
- Exenatide and renal failure.
- An experimental study of exenatide effects on renal injury in diabetic rats1.
- Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus: A post-hoc analysis of a 52-week randomised trial.
- Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL.
- SIRT1-dependent deacetylation of Txnip H3K9ac is critical for exenatide-improved diabetic kidney disease.
- Comparison of nephron-protective effects of enalapril and GLP analogues (exenatide) in diabetic nephropathy.